Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2017 07:00 ET | Source: ObsEva SA

ObsEva SA to Attend Jefferies Healthcare Conference in NYC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA - 31...
May 18, 2017 07:00 ET | Source: ObsEva SA

ObsEva Reports First Quarter 2017 Financial Results and Business Update

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Phase 3 Programs Underway in Uterine...
May 18, 2017 06:30 ET | Source: ObsEva SA

ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - OBE022 is ObsEva's potential...
May 16, 2017 07:00 ET | Source: ObsEva SA

ObsEva SA to Attend BioEquity Europe 2017 in Paris

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - 16 May 2017 -...
May 11, 2017 07:00 ET | Source: ObsEva SA

ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
April 25, 2017 07:00 ET | Source: ObsEva SA

ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - PRIMROSE 1 and PRIMROSE 2, pivotal...
March 24, 2017 12:00 ET | Source: ObsEva SA

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - 24 March 2017 -...
March 17, 2017 07:00 ET | Source: ObsEva SA

ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - OBE022 is ObsEva's potential...
March 07, 2017 07:00 ET | Source: ObsEva SA

ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - IMPLANT2 study to confirm efficacy and...
February 03, 2017 07:00 ET | Source: ObsEva SA

ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - February 03,...